Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vodudeutentan · ENB003

Small molecule · Antagonist of endothelin B receptor (EDNRB)

Phase 2 Most advanced trial
1 Registered trials

What is Vodudeutentan?

Vodudeutentan is an antagonist of the endothelin B receptor (ETBR, EDNRB), a G-protein coupled receptor overexpressed on many tumor cell types. It binds ETBR on tumor cells, blocking ETBR-mediated signaling that supports proliferation, invasion and immunosuppression. It is studied in ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ENB003
Drug type
Small molecule
Targets
endothelin B receptor (EDNRB)
Mechanism
Antagonist of endothelin B receptor (EDNRB)
Pathways
tumor cell proliferation, epithelial-mesenchymal transition, angiogenesis, T-cell trafficking
Therapy area
Oncology
In trials of
AZN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
2YCH69X4OX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04918186 Phase 2 Ovarian Cancer Recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian Cancer

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.